Arca
Skip to content
Tools
Tools

OBSIDIO™ Conformable Embolic (M0013972101010)

Device, Vascular, For Promoting Embolization. 510(k) K253376, from Boston Scientific Corporation (Maple Grove, MN). Product code KRD, class 2.

As of Nov 18, 2026, K253376 is an FDA 510(k) held by Boston Scientific Corporation, substantially equivalent on Oct 30, 2025 after 30 days, with no recalls tied to it in FDA's recall database.

  • Review time: 30 days
  • Recalls: 0

Indications for use

As the 510(k) summary states them, read from FDA's summary PDF

The OBSIDIO™ Conformable Embolic is indicated for use in the embolization of: • Hypervascular tumors • Blood vessels to occlude blood flow for controlling bleeding/hemorrhaging in the peripheral vasculature

Predicate devices

The legally marketed devices this 510(k) summary says it is substantially equivalent to, read from FDA's summary PDF

Other KRD clearances

The newest 510(k)s for the same product code; their median review was 70 days; see every KRD device

Record

Type
Special
Received
Sep 30, 2025
Review panel
Cardiovascular
Regulation
21 CFR 870.3300

One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.